Literature DB >> 23793291

Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.

James I Fells1, Sue Chin Lee, Yuko Fujiwara, Derek D Norman, Keng Gat Lim, Ryoko Tsukahara, Jianxiong Liu, Renukadevi Patil, Duane D Miller, R Jason Kirby, Sandra Nelson, William Seibel, Ruben Papoian, Abby L Parrill, Daniel L Baker, Robert Bittman, Gabor Tigyi.   

Abstract

Autotaxin (ATX), a lysophospholipase D, plays an important role in cancer invasion, metastasis, tumor progression, tumorigenesis, neuropathic pain, fibrotic diseases, cholestatic pruritus, lymphocyte homing, and thrombotic diseases by producing the lipid mediator lysophosphatidic acid (LPA). A high-throughput screen of ATX inhibition using the lysophosphatidylcholine-like substrate fluorogenic substrate 3 (FS-3) and ∼10,000 compounds from the University of Cincinnati Drug Discovery Center identified several small-molecule inhibitors with IC₅₀ vales ranging from nanomolar to low micromolar. The pharmacology of the three most potent compounds: 918013 (1; 2,4-dichloro-N-(3-fluorophenyl)-5-(4-morpholinylsulfonyl) benzamide), 931126 (2; 4-oxo-4-{2-[(5-phenoxy-1H-indol-2-yl)carbonyl]hydrazino}-N-(4-phenylbutan-2-yl)butanamide), and 966791 (3; N-(2,6-dimethylphenyl)-2-[N-(2-furylmethyl)(4-(1,2,3,4-tetraazolyl)phenyl)carbonylamino]-2-(4-hydroxy-3-methoxyphenyl) acetamide), were further characterized in enzyme, cellular, and whole animal models. Compounds 1 and 2 were competitive inhibitors of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3. In contrast, compound 3 was a competitive inhibitor of both FS-3 and the phosphodiesterase substrate p-nitrophenyl thymidine 5'-monophosphate. Computational docking and mutagenesis suggested that compounds 1 and 2 target the hydrophobic pocket, thereby blocking access to the active site of ATX. The potencies of compounds 1-3 were comparable to each other in each of the assays. All of these compounds significantly reduced invasion of A2058 human melanoma cells in vitro and the colonization of lung metastases by B16-F10 murine melanoma cells in C57BL/6 mice. The compounds had no agonist or antagonist effects on select LPA or sphingosine 1-phosphate receptors, nor did they inhibit nucleotide pyrophosphatase/phosphodiesterase (NPP) enzymes NPP6 and NPP7. These results identify the molecular surface of the hydrophobic pocket of ATX as a target-binding site for inhibitors of enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23793291      PMCID: PMC3876816          DOI: 10.1124/mol.113.087080

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  47 in total

1.  AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.

Authors:  Oleg Trott; Arthur J Olson
Journal:  J Comput Chem       Date:  2010-01-30       Impact factor: 3.376

2.  Intestinal alkaline sphingomyelinase hydrolyses and inactivates platelet-activating factor by a phospholipase C activity.

Authors:  Jun Wu; Ake Nilsson; Bo A G Jönsson; Hanna Stenstad; William Agace; Yajun Cheng; Rui-Dong Duan
Journal:  Biochem J       Date:  2006-02-15       Impact factor: 3.857

3.  Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.

Authors:  Daniel L Baker; Yuko Fujiwara; Kathryn R Pigg; Ryoko Tsukahara; Susumu Kobayashi; Hiromu Murofushi; Ayako Uchiyama; Kimiko Murakami-Murofushi; Eunjin Koh; Russell W Bandle; Hoe-Sup Byun; Robert Bittman; Dominic Fan; Mandi Murph; Gordon B Mills; Gabor Tigyi
Journal:  J Biol Chem       Date:  2006-06-16       Impact factor: 5.157

4.  Autotaxin expression in non-small-cell lung cancer.

Authors:  Y Yang; Lj Mou; N Liu; M S Tsao
Journal:  Am J Respir Cell Mol Biol       Date:  1999-08       Impact factor: 6.914

5.  Biochemical and molecular characterization of a novel choline-specific glycerophosphodiester phosphodiesterase belonging to the nucleotide pyrophosphatase/phosphodiesterase family.

Authors:  Hideki Sakagami; Junken Aoki; Yumiko Natori; Kiyotaka Nishikawa; Yoshiyuki Kakehi; Yasuhiro Natori; Hiroyuki Arai
Journal:  J Biol Chem       Date:  2005-03-23       Impact factor: 5.157

6.  Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.

Authors:  Lauren P Saunders; Amy Ouellette; Russ Bandle; William Chozen Chang; Hongwen Zhou; Raj N Misra; Enrique M De La Cruz; Demetrios T Braddock
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

7.  Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

Authors:  Marion David; Estelle Wannecq; Françoise Descotes; Silvia Jansen; Blandine Deux; Johnny Ribeiro; Claire-Marie Serre; Sandra Grès; Nathalie Bendriss-Vermare; Mathieu Bollen; Simone Saez; Junken Aoki; Jean-Sébastien Saulnier-Blache; Philippe Clézardin; Olivier Peyruchaud
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

8.  Optimization of a pipemidic acid autotaxin inhibitor.

Authors:  Adrienne B Hoeglund; Heidi E Bostic; Angela L Howard; Irene W Wanjala; Michael D Best; Daniel L Baker; Abby L Parrill
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

9.  Expression of autotaxin and acylglycerol kinase in prostate cancer: association with cancer development and progression.

Authors:  Mohammed Ahmed Abdel Muneem Nouh; Xiu-Xian Wu; Homare Okazoe; Hiroyuki Tsunemori; Reiji Haba; Abdel Muneem Mohammed Abou-Zeid; Mohammed Diaa Saleem; Masashi Inui; Mikio Sugimoto; Junken Aoki; Yoshiyuki Kakehi
Journal:  Cancer Sci       Date:  2009-05-31       Impact factor: 6.716

10.  S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool.

Authors:  Gilles Ferry; Natacha Moulharat; Jean-Philippe Pradère; Patrice Desos; Anne Try; Annie Genton; Adeline Giganti; Monique Beucher-Gaudin; Michel Lonchampt; Marc Bertrand; Jean-Sébastien Saulnier-Blache; Gordon C Tucker; Alex Cordi; Jean A Boutin
Journal:  J Pharmacol Exp Ther       Date:  2008-08-28       Impact factor: 4.030

View more
  10 in total

Review 1.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

Review 2.  Chemical modulation of glycerolipid signaling and metabolic pathways.

Authors:  Sarah A Scott; Thomas P Mathews; Pavlina T Ivanova; Craig W Lindsley; H Alex Brown
Journal:  Biochim Biophys Acta       Date:  2014-01-15

Review 3.  Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.

Authors:  Gabor J Tigyi; Leonard R Johnson; Sue Chin Lee; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Karin Thompson; Alyssa Boler; W Shannon McCool
Journal:  J Lipid Res       Date:  2019-01-28       Impact factor: 5.922

4.  Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone.

Authors:  Raphael Leblanc; Sue-Chin Lee; Marion David; Jean-Claude Bordet; Derek D Norman; Renukadevi Patil; Duane Miller; Debashish Sahay; Johnny Ribeiro; Philippe Clézardin; Gabor J Tigyi; Olivier Peyruchaud
Journal:  Blood       Date:  2014-10-02       Impact factor: 22.113

5.  Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif.

Authors:  James I Fells; Sue Chin Lee; Derek D Norman; Ryoko Tsukahara; Jason R Kirby; Sandra Nelson; William Seibel; Ruben Papoian; Renukadevi Patil; Duane D Miller; Abby L Parrill; Truc-Chi Pham; Daniel L Baker; Robert Bittman; Gabor Tigyi
Journal:  FEBS J       Date:  2014-01-15       Impact factor: 5.542

Review 6.  Autotaxin: structure-function and signaling.

Authors:  Anastassis Perrakis; Wouter H Moolenaar
Journal:  J Lipid Res       Date:  2014-02-18       Impact factor: 5.922

7.  Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.

Authors:  Lauren E Ragle; Dilip J Palanisamy; Margaux J Joe; Rachel S Stein; Derek D Norman; Gabor Tigyi; Daniel L Baker; Abby L Parrill
Journal:  Bioorg Med Chem       Date:  2016-08-04       Impact factor: 3.641

8.  Molecular modelling guided design, synthesis and QSAR analysis of new small molecule non-lipid autotaxin inhibitors.

Authors:  Souvik Banerjee; Derek D Norman; Shanshan Deng; Sayo O Fakayode; Sue Chin Lee; Abby L Parrill; Wei Li; Duane D Miller; Gabor J Tigyi
Journal:  Bioorg Chem       Date:  2020-08-26       Impact factor: 5.275

Review 9.  Promising pharmacological directions in the world of lysophosphatidic Acid signaling.

Authors:  Nicole C Stoddard; Jerold Chun
Journal:  Biomol Ther (Seoul)       Date:  2015-01-01       Impact factor: 4.634

10.  Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.

Authors:  Christiana Magkrioti; Eleanna Kaffe; Elli-Anna Stylianaki; Camelia Sidahmet; Georgia Melagraki; Antreas Afantitis; Alexios N Matralis; Vassilis Aidinis
Journal:  Int J Mol Sci       Date:  2020-09-23       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.